ISSN:0971-1260

Vol-22-Issue-14-December-2019

Physiological Consequences Of A Diabetic Retina And Innovative Medical Care Prospects, A Review.

Gaurav Saxena*[1], Sudhir Mishra[1] and Nutan[2]

1. IIMT College of Pharmacy, Greater Noida, Uttar Pradesh 201308
2. HIMT College of Pharmacy, Greater Noida (U P) India

Abstract: Diabetes is a medical condition and has severe effects on the body. Quite precisely, diabetes can cause permanent damage to the eye. Several of these damage caused often include retinopathy, macular edema, cataracts, glaucoma, and sometimes even blindness.But while the consequences of eye diabetes could be quite intense, if treated early on, the ailment can be regulated and managed.

Keywords: Diabetes mellitus, Cataracts, Glaucoma, Macular Edema, Retinopathy,

Introduction

Diabetes is a severe metabolic disorder which, when uncontrolled and neglected, it could be the basis of a whole gamut of damage throughout the body. Diabetes is negatively impacting millions of people all around the world. In particular, diabetes can cause immense harm to the eye. Diabetes can trigger fundamental and functional failure to eyesight if left unaddressed. Such damages include cataract, retinopathy for diabetes, diabetic macular oedema, and glaucoma. Patients with diabetic retinopathy are twenty-five times more likely to develop blindness than nondiabetics. [1,2]

DIABETES

Diabetes mellitus is a disorder that affects insulin secretion, resulting in increased blood glucose (hyperglycemia), as per the World Health Organization (WHO). Insulin-dependent diabetes mellitus (IDDM) most commonly occurs in children and is generally genetic. In IDDM, the pancreas would not output optimal levels of insulin, so needs direct supplementation by an insulin pump or pen.

Type two diabetes (NIDDM) is perhaps the most common forms of Mellitus, contributing to 90% for all instances of diabetes. This kind of diabetes results once the individual is not sufficiently receptive to the action of insulin.

ISSN:0971-1260

Vol-22-Issue-14-December-2019

Classic symptoms of diabetes tend to involve excessive urination, intensified thirst, disproportionate cravings, abnormal weight loss, irritability, persistent fatigue, and blurry vision.[3]

Ketoacidosis or even a quasi-ketotic hyper-osmolar syndrome can evolve and at its most extreme forms, progressing to stupor, coma and mortality in the unavailability of appropriate treatment. However, insulin deficiency can be chronic and if health problems are often not significant or missing; diabetes could cause systemic pathological and functional changes to occur well before the diagnosis is made.[4]

After two decades of inception of diabetes, nearly all patients with IDDM and more than 60% of NIDDM patients would have retinopathy. The two standard tests measure the extent of retinopathy is the Early Treatment Diabetic Retinopathy Study (ETDRS) classical stage model and the International Opthalmology Council's recently developed method. The severity scale of ETDRS is based on the revised diabetic retinopathy category of Airlie House, which is used for scoring fundus images. Despite being accepted as the benchmark for evaluating the gravity of diabetic retinopathy, the ETDRS staging procedure the utility for practical routine usage is disputed .[5] To overcome this problematic issue, the International Council of Ophthalmology has created an international scale to bridge gaps between global ophthalmologists as well as physicians and provide a standard, user-friendly phraseology to illustrate the magnitude of the condition. In this new scale, there are five categories in the context of enormity of diabetic retinopathy, based on observations noted by dilated ophthalmoscopy. The initial stage, "no obvious retinopathy" to "mild non-proliferative diabetic retinopathy (NPDR)," distinguished by increased vascular permeability, and only microaneurysms are observed; later evolves to "moderate and extreme non-proliferative diabetic retinopathy (NPDR)," identified by vascular closure with indications of intraretinal microvascular abnormalities. The fifth stage is "Proliferative Diabetic Retinopathy (PDR)" with signs of neo-vascularisation on the retina and posterior surface of the vitreous or vitreous / pre-retinal haemorrhage. [5, 6]

Diabetic Eye and Therapies

CATARACT

The role of the lens is to transmit and focus light on the retina. Therefore, it must be transparent. A cataract is the incremental lens opacity. The initial indication of the cataract is

ISSN:0971-1260

Vol-22-Issue-14-December-2019

blurred vision, and other symptoms include blurred vision, colour fading, excessive light glare, diminished night vision, as well as double vision.[7] The principal varieties are nuclear, cortical and posterior sub-capsulated cataracts. The opacities that develop from the outer layers of the lens are cortical cataracts. It typically shows over-hydration and ultimately liquefaction of the lens fibre cells owing to the electrolyte imbalance. A nuclear cataract occurs when lens structural proteins are altered and disseminated to establish light-scattering areas in the lens ' central region. Posterior subcapsular cataract (PSC) is characterised as an excess of the irregular epithelium at the rear of the lens or within the capsule. Most patients would develop only cortical, nuclear and PSC cataracts. Nevertheless, mixed cataracts are also widespread. (Bunce, 1994)[8]. It is are easily detected by an ophthalmologist, epitomised by the white "nebulosity" of the lens. Additional tests for cataract diagnosis include regular visual acuity check, dilated eye exam as well as tonometry (intraocular pressure measurement). [7]

A build-up of sorbitol in the eye's lens induces diabetic cataracts. An enzyme, aldose reductase, converts glucose to sorbitol. However, when the sorbitol dehydrogenase enzyme does not decompose sorbitol to fructose at that same level that equals glucose reduction, it initiates sorbitol concentration in the lens. Osmotic pressure triggers a massive influx of water into the lens cells due to the increased levels of sorbitol throughout the lens and “collapse and liquefaction of lens fibres”.[9]

Therapeutic approaches for the management of diabetic cataracts are not available. The only definitive option is to extract cataracts surgically then substitute the lens with an IOL (intraocular lens). The IOL is often a tiny acrylic "biconvex optic,", which will operate as the substitute lens. It does have two arm-like constructs termed haptics that enable IOL to cling to the wall of the eye to keep its place (Fuller, 2013)[10]. Even if the complications of cataract could be eliminated via surgery, the key to avoiding a diabetic cataract is the prevention of recurrent high blood sugar.

ISSN:0971-1260

Vol-22-Issue-14-December-2019



Figure 1: "Cataract Surgery."

DIABETIC RETINOPATHY

Diabetic retinopathy triggers deterioration to the retina over time due to increased sugar levels in the eye. The retina receives visual stimuli, later conveys them to the brain as neuronal signals. Because constant high concentrations of glucose persist in the eye, capillaries and small eye vessels eventually develop weaknesses and/or openings. It ultimately triggers the eye's fluid to overflow onto the eye's backspace. This leakage causes inflammation of the retina, resulting in reduced sight.

ISSN:0971-1260

Vol-22-Issue-14-December-2019



Figure 2:Diabetic Retinopathy Compared to Normal Eye

Diabetic retinopathy has two basic categories: proliferative and non-proliferative. Non-proliferative diabetic retinopathy is the initial stage, in which accumulated glucose in the eye causes the vessels to weaken and form microaneurysms. Glucose from outside the cell will move inside to restore homeostatic levels due to the osmotic pressure. The excessive glucose is then processed by aldose reductase onto sorbitol.[7] Sorbitol accumulates, it induces a hypertonic solution within the cells, culminating in cell swelling and bursting (lyse). Cell lysis undermines the walls of the vessel that provoke leakage and is the root cause of retinopathy. Proliferative diabetic retinopathy is the severe form typified by oxygen deprivation in the eye, likely to result in tissue necrosis and blindness. Retinal detachment due to the massive injury is a critical complication of proliferative diabetic retinopathy, which needs surgical intervention for resolution.[9]

CURE

There are many ways to manage retinopathy, including medications, procedure even homoeopathic remedies. An anti-vascular endothelial growth factor (anti-VEGF) is, by far the most popular type of medicine to treat diabetic retinopathy. Lucentis®, Avastin®, and Eylea® are the most common drug formulations injected into the eye for the management of diabetic retinopathy. Such products are not a fix for retinopathy, but they might help alleviate the problems tremendously.[10] Frequently, treating diabetic retinopathy through surgical vitrectomy is better than most other interventions. A vitrectomy is a surgical excision in the back of the eye of the jelly-like material. In patients with significant bleeding in the vitreous humour, posterior vitrectomy is indicated.[11] Diabetic retinopathy can be cured if diagnosed

ISSN:0971-1260

Vol-22-Issue-14-December-2019

early and inflict little if any substantial damage of the retina. Also, proper exercise and diet can help prevent diabetes and reduce eye damage.

DIABETIC MACULAR EDEMA (DME)

Diabetic macular oedema is a disease that involves the macula, which in itself is a section of a retina in the middle of the back of the eye. Analogous to diabetic retinopathy, it develops inflammation of the macula when the eye vessels become inflamed and leak fluids into the vitreal cavity. Like in diabetic retinopathy, the eye is affected, although the macula tissues are damaged in-specific.[8]



Figure 3 Diabetic Macular Edema

CURE

The medical approach to diabetic macular oedema (DME) is similar to diabetic retinopathy, as is the causative agents and progression of both ailments. Physicians might also incorporate a corticosteroid to the regiment with DME. Corticosteroids help alleviate oedema between injections besides reduce periodic injection needs and could be dispensed as a tablet, drop or intramuscular injection. To more extreme cases of DME, the medical specialist can always choose an implantable steroid release system.

Surgical excision for DME is emphasised if the macula has become inflamed, sight is most often completely blocked. Vitrectomy is done to extract the impaired vitreous, as well as any persistent bleeding vessels, maybe cauterised with a laser. The specialist will ascertain necessity silicone or gas to substitute the depleted vitreous once all active bleeding and damaged vitreous are managed. Management of DME can be accomplished with anti-inflammatory drugs, surgery, and appropriate exercise and diet. Although ailment is not

ISSN:0971-1260

Vol-22-Issue-14-December-2019

untreatable, proper management could allow people to have the right vision. Immediate surgery when blind spots first appear may help to prevent permanent blindness.

GLAUCOMA

Glaucoma is typified as an anomalous condition of intense pressure in the eye. There are many situations where the intraocular tension of the eye is elevated. Open-angle glaucoma and acute narrow-angle glaucoma are the most commonly known types of glaucoma. However, neovascular glaucoma (NVG) is most typically detected in diabetic patients. NVG is described as a supplementary manifestation of glaucoma as it is originating due to diabetic retinopathy. As pointed out earlier, diabetic retinopathy is the seepage of this liquid that induces the retina to be inflamed, contributing to the creation of new, weakened arteries expanding onto the iris triggering NVG. The track in which the aqueous humour circulates to the anterior chamber is impeded by the iris due to new vasculature and is analogous to the acute narrow-angle glaucoma.[12]



Figure 4, Neovascular Glaucoma

CURE

There are a variety of ways to survive neovascular glaucoma. The comprehensive handling of NVG is a two-pronged strategy which comprises medical and surgical therapy, together with the long-term prevention of fresh vascularisation on the iris. Neovascular glaucoma tension can sometimes be regulated with several medications, including beta-blockers, carbonic anhydrase inhibitors, that operate by "reducing aqueous output and potentially increasing

ISSN:0971-1260

Vol-22-Issue-14-December-2019

uveoscleral outflow". Much like diabetic retinopathy, corticosteroids may be administered can eye drops or oral medication to reduce excessive inflammation.

TCM (Traditional Chinese Medicines) as potential anti-diabetic retinopathy treatment

For the effects on ocular blood flow, a multitude of natural products have been investigated. Several experimental studies have proven the benefits of herbal medicine in minimising pain, boosting visual acuity, including visible range, including enhancing ophthalmoscopy impressions. A few of them are potent agents that cause significant changes in ocular blood flow, particularly the choroidal as well as retinal blood flow. Some are isolated from medicinal plants which were explicitly used cardiovascular diseases, circulation stasis, visual acuity enhancement, and so on. Numerous active ingredients from native plants were identified. Many preclinical and clinical studies have been done to explore the molecular mechanism of the outcome. *Ganoderma applanatum* not just to suppress *in vitro* aldose reductase, but also decreased the accumulation of serum glucose and sorbitol in diabetic rats. [15] Effective use of herbal therapies could be a catalyst in curbing the incidence and progression of this sight-threatening complication in diabetic patients.[16]

References

1.Raman R, Rani P, Reddi RS. Prevalence of diabetic retinopathy in India: Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetics Study report 2. Ophthalmol 2009; 116: 311–318.

2. Sloan FA, Belsky D, Ruiz D, Lee P. Changes in incidence of diabetes mellitus-related eye disease among US elderly persons 1994–2005. Arch Ophthalmol 2008; 126: 1548–1553.

3. “Diabetes, Mellitus.” World Health Organization, World Health Organization, 22 Nov. 2010, www.who.int/mediacentre/factsheets/fs138/en/.

4. “Type 1 Diabetes.” Mayo Clinic, Mayo Foundation for Medical Education and Research, 7 Aug. 2017, www.mayoclinic.org/diseases-conditions/type-1-diabetes/symptoms-causes/syc-20353011.

5. Fong DS, Aiello LP, Ferris FL 3rd, Klein R. Diabetic retinopathy. Diabetes Care 2004;27(10):2540–53.

ISSN:0971-1260

Vol-22-Issue-14-December-2019

6. International Council of Ophthalmology (ICO). International clinical diabetic retinopathy disease severity scale, detailed table. www.icoph.org/standards/pdrdetail.html (accessed 25 October 2019).

7. National Eye Institute (NEI). "Facts About Macular Edema." National Eye Institute, National Eye Institute and National Institutes of Health, Oct. 2015, nei.nih.gov/health/macular-edema/fact_sheet.

8. Bunce, G. E. Nutrition and eye disease of the elderly. Journal of Nutritional Biochemistry 1994 5(1): 66-77.

9. Pollreisz, Andreas, and Ursula Schmidt-Erfurth. "Diabetic Cataract—Pathogenesis, Epidemiology and Treatment." Journal of Ophthalmology, (2010), 608751, pp. 1–8.

10. Armistead, Julie, editor. "Ophthalmic Surgery." Surgical Technology: Principles and Practice, by Joanna Ruth. Fuller, 6th ed., Elsevier Saunders, 2013, 652–684.

11. American Optometric Association. "Diabetic Retinopathy." American Optometric Association (AOA), 2018, www.aoa.org/patients-and-public/eye-and-vision-problems/glossary-of-eye-and-vision-conditions/diabetic-retinopathy.

12. Yorston, David. "Anti-VEGF Drugs in the Prevention of Blindness." Community Eye Health Journal, 27, 87, 2014, pp. 44–46.

13. Helbig, Horst, and Florian K. P. Sutter. "Surgical Treatment of Diabetic Retinopathy." Graefe's Archive for Clinical and Experimental Ophthalmology, 242, 8, 2004, 704–709.

14. Rodrigues, Gustavo B., et al. "Neovascular Glaucoma: a Review." International Journal of Retina and Vitreous, vol. 2, no. 1, 14 Nov. 2016, pp. 1–10.15. Jung SH, et al.Inhibitory effects of *Ganoderma applanatum* on rat lens aldose reductase and sorbitol accumulation in streptozotocin-induced diabetic rat tissues. Phytotherapy Research 2005;19(6):477–80.

15.West AL, Oren GA, Moroi SE. Evidence for the use of nutritional supplements and herbal medicines in common eye diseases. American Journal of Ophthalmology 2006;141 (1):157–66.